clinical trial · NCT04295447
Adjuvant Apalutamide in Subjects With High-risk Localized or Locally Advanced Prostate Cancer After Radical Prostatectomy
Universität Münster·phase2·active not recruiting·n = 190
Prostatic NeoplasmsStandard of careApalutamide 60Mg Tab
brief summary
The primary objective of this trial is to determine if adjuvant apalutamide in prostate cancer patients at high risk of developing subsequent metastatic disease results in prolonged biochemically recurrence-free survival after radical prostatectomy (RPE) in comparison to standard of care (SOC).
started
Dec 10, 2020
primary completion
Nov 30, 2028
completion
Nov 30, 2028
last updated
Jun 20, 2024
official title
A Randomized, Open-label, Phase 2 Study of Adjuvant Apalutamide or Standard of Care in Subjects With High-risk, Localized or Locally Advanced Prostate Cancer After Radical Prostatectomy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol